Trial Profile
Congenital Cytomegalovirus: Efficacy of Antiviral Treatment in a Randomized Controlled Trial [CONgenitale Cmv: Effectiviteit van antivirale therapie in een geRandomiseerde gecontroleerd Trial]
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 22 Jul 2022
Price :
$35
*
At a glance
- Drugs Valganciclovir (Primary)
- Indications Cytomegalovirus infections; Sensorineural hearing loss
- Focus Therapeutic Use
- Acronyms CONCERT
- 04 Nov 2013 Planned end date changed from 1 Jun 2015 to 1 Jun 2014 as reported by ClinicalTrials.gov.
- 04 Nov 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 03 Aug 2012 Planned end date changed from 3 May 2015 to 1 Jun 2015 as reported by ClinicalTrials.gov.